Piper Sandler reiterates BridgeBio stock rating on patent settlement By Investing.com

Piper Sandler reiterated an Overweight rating on BridgeBio Pharma with a $111 price target, implying upside from the recent $74.68 share price and $14.6 billion market cap. The firm said Pfizer’s settlement with Cipla reduces the risk of earlier generic tafamidis entry, which is constructive for BridgeBio’s Attruby franchise. Other analysts also remain constructive, with price targets ranging from $100 to $106 and attention focused on upcoming patent litigation and first-quarter sales updates.

Analysis

The key second-order effect is not just de-risking for BBIO, but a meaningful extension of the market’s assumed exclusivity window for tafamidis-adjacent economics. If the challenger universe keeps collapsing into isolated litigation, the probability distribution shifts toward a later cliff, which supports higher confidence in BridgeBio’s launch curve and pricing discipline over the next 6-18 months. That matters more than the near-term headline because the stock is still being valued as if a late-2028 overhang is plausible; compressing that tail risk can justify multiple expansion even before revenue beats show up.

For PFE, the issue is less the single settlement and more the signaling effect: each additional resolution lowers the probability that the remaining litigant extracts a near-term settlement on attractive terms. The market may be underestimating how patent settlements can become a sequence of diminishing bargaining power rather than a binary event. If the trial outcome is favorable to Pfizer, the implied duration of the franchise improves materially; if not, the downside is not just earlier generic entry, but a faster erosion of pricing flexibility across the amyloidosis category.

The contrarian angle is that the bullish read on BBIO may be partially crowded already, with sell-side targets clustering in a narrow band and the catalyst path now more patent-event driven than fundamental. That creates a setup where the stock can grind higher on reduced legal risk, but the asymmetry is best expressed through options or pairs rather than outright spot given binary legal headlines and likely volatility compression after each settlement. Near-term, the market should focus on the Hikma trial outcome and any language around settlement timing; those are the next inflection points that can either extend the rerating or reintroduce the 2028 overhang quickly.

Key Decisions for Investors

• Go long BBIO versus short PFE as a 1-3 month relative-value trade; thesis is that each additional challenger settlement lowers perceived tafamidis generic risk and supports BBIO’s multiple more than it hurts PFE, which still carries the overhang.
• Buy BBIO call spreads 2-6 months out to express the legal-risk de-risking without paying full delta; best risk/reward is on a move higher as settlement probability improves, with defined premium at risk.
• Trim or hedge any unhedged PFE long ahead of the Hikma trial window; the asymmetry has shifted from settlement optionality to headline gap risk if the court dynamic turns against Pfizer.
• If BBIO spikes on trial headlines, sell strength into the first 5-10% move and rotate into longer-dated upside structures; the crowding risk makes spot less attractive than convexity.
• Set a catalyst alert around the trial start and any post-trial commentary; a favorable read-through could justify adding BBIO on a 3-6 month horizon, while an adverse outcome argues for taking profits quickly.